News >

FDA Grants Larotrectinib Priority Review for NTRK+ Cancers

Jason M. Broderick @jasoncology
Published: Tuesday, May 29, 2018

Anna F. Farago, MD, PhD

Anna F. Farago, MD, PhD
The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.

UPDATE 11/26/2018: FDA Approves Larotrectinib for NTRK+ Cancers

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication